25 XP   0   0   10

Coherus BioSciences Inc
Buy, Hold or Sell?

Let's analyze Coherus together

I guess you are interested in Coherus BioSciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Coherus BioSciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Coherus BioSciences Inc

I send you an email if I find something interesting about Coherus BioSciences Inc.

Quick analysis of Coherus (30 sec.)










What can you expect buying and holding a share of Coherus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-0.65
Expected worth in 1 year
$0.41
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$1.06
Return On Investment
76.3%

For what price can you sell your share?

Current Price per Share
$1.39
Expected price per share
$0 - $1.84
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Coherus (5 min.)




Live pricePrice per Share (EOD)

$1.39

Intrinsic Value Per Share

$-28.80 - $-16.79

Total Value Per Share

$-29.45 - $-17.45

2. Growth of Coherus (5 min.)




Is Coherus growing?

Current yearPrevious yearGrowGrow %
How rich?-$81.8m-$113.4m-$32.4m-22.3%

How much money is Coherus making?

Current yearPrevious yearGrowGrow %
Making money-$14.8m-$72.5m$57.7m389.4%
Net Profit Margin-19.9%-168.7%--

How much money comes from the company's main activities?

3. Financial Health of Coherus (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#944 / 966

Most Revenue
#90 / 966

Most Profit
#637 / 966

Most Efficient
#360 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Coherus? (5 min.)

Welcome investor! Coherus's management wants to use your money to grow the business. In return you get a share of Coherus.

What can you expect buying and holding a share of Coherus?

First you should know what it really means to hold a share of Coherus. And how you can make/lose money.

Speculation

The Price per Share of Coherus is $1.39. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Coherus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Coherus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.65. Based on the TTM, the Book Value Change Per Share is $0.27 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Coherus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.8259.0%-0.15-10.7%-0.59-42.5%-0.21-15.1%-0.39-28.2%
Usd Book Value Change Per Share1.0374.4%0.2719.1%-0.46-32.8%-0.02-1.1%-0.01-0.5%
Usd Dividend Per Share0.000.0%0.000.0%0.117.7%0.021.5%0.010.8%
Usd Total Gains Per Share1.0374.4%0.2719.1%-0.35-25.0%0.010.4%0.000.3%
Usd Price Per Share2.39-3.43-7.90-12.44-14.57-
Price to Earnings Ratio0.73--1.51--3.44-4.15--1.30-
Price-to-Total Gains Ratio2.31-7.22--25.79-9.01-545.32-
Price to Book Ratio-3.67--2.91--14.67--21.73--14.00-
Price-to-Total Gains Ratio2.31-7.22--25.79-9.01-545.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.39
Number of shares719
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share0.27-0.02
Usd Total Gains Per Share0.270.01
Gains per Quarter (719 shares)190.694.10
Gains per Year (719 shares)762.7516.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1076375362-456
2015261516124-9122
3022882279186-13638
4030513042248-18254
5038143805309-22770
6045774568371-27386
7053395331433-318102
8061026094495-364118
9068656857557-409134
10076287620619-455150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%8.012.00.040.0%9.031.00.022.5%9.034.01.020.5%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%11.09.00.055.0%20.020.00.050.0%21.021.02.047.7%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.042.04.5%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%11.09.00.055.0%20.020.00.050.0%21.021.02.047.7%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Coherus

About Coherus BioSciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2024-06-17 17:31:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Coherus BioSciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Coherus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • A Net Profit Margin of 133.5% means that $1.33 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Coherus BioSciences Inc:

  • The MRQ is 133.5%. The company is making a huge profit. +2
  • The TTM is -19.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ133.5%TTM-19.9%+153.4%
TTM-19.9%YOY-168.7%+148.7%
TTM-19.9%5Y-54.1%+34.1%
5Y-54.1%10Y-1,824.2%+1,770.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ133.5%-168.0%+301.5%
TTM-19.9%-209.9%+190.0%
YOY-168.7%-242.3%+73.6%
5Y-54.1%-401.7%+347.6%
10Y-1,824.2%-532.2%-1,292.0%
1.1.2. Return on Assets

Shows how efficient Coherus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • 13.5% Return on Assets means that Coherus generated $0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Coherus BioSciences Inc:

  • The MRQ is 13.5%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ13.5%TTM-3.8%+17.2%
TTM-3.8%YOY-14.9%+11.1%
TTM-3.8%5Y-4.0%+0.2%
5Y-4.0%10Y-14.7%+10.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.5%-11.9%+25.4%
TTM-3.8%-11.9%+8.1%
YOY-14.9%-11.3%-3.6%
5Y-4.0%-13.5%+9.5%
10Y-14.7%-14.9%+0.2%
1.1.3. Return on Equity

Shows how efficient Coherus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • 0.0% Return on Equity means Coherus generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Coherus BioSciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-46.5%+46.5%
5Y-46.5%10Y-69.7%+23.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.7%+15.7%
YOY--14.3%+14.3%
5Y-46.5%-19.2%-27.3%
10Y-69.7%-19.7%-50.0%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Coherus BioSciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Coherus is operating .

  • Measures how much profit Coherus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • An Operating Margin of -46.4% means the company generated $-0.46  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Coherus BioSciences Inc:

  • The MRQ is -46.4%. The company is operating very inefficient. -2
  • The TTM is -55.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-46.4%TTM-55.3%+9.0%
TTM-55.3%YOY-143.2%+87.9%
TTM-55.3%5Y-50.5%-4.8%
5Y-50.5%10Y-1,770.1%+1,719.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.4%-354.6%+308.2%
TTM-55.3%-225.9%+170.6%
YOY-143.2%-252.2%+109.0%
5Y-50.5%-428.3%+377.8%
10Y-1,770.1%-531.1%-1,239.0%
1.2.2. Operating Ratio

Measures how efficient Coherus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.46 means that the operating costs are $1.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Coherus BioSciences Inc:

  • The MRQ is 1.464. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.557. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.464TTM1.557-0.093
TTM1.557YOY2.432-0.875
TTM1.5575Y1.505+0.052
5Y1.50510Y35.914-34.410
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4643.004-1.540
TTM1.5573.332-1.775
YOY2.4323.502-1.070
5Y1.5055.271-3.766
10Y35.9146.915+28.999
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Coherus BioSciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Coherus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.17 means the company has $1.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Coherus BioSciences Inc:

  • The MRQ is 1.166. The company is just able to pay all its short-term debts.
  • The TTM is 1.682. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.166TTM1.682-0.516
TTM1.682YOY4.905-3.223
TTM1.6825Y4.179-2.497
5Y4.17910Y3.802+0.377
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1663.767-2.601
TTM1.6824.000-2.318
YOY4.9054.9050.000
5Y4.1795.883-1.704
10Y3.8026.286-2.484
1.3.2. Quick Ratio

Measures if Coherus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • A Quick Ratio of 1.01 means the company can pay off $1.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Coherus BioSciences Inc:

  • The MRQ is 1.010. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.492. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.010TTM1.492-0.482
TTM1.492YOY4.752-3.260
TTM1.4925Y4.101-2.609
5Y4.10110Y3.750+0.351
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0103.054-2.044
TTM1.4923.506-2.014
YOY4.7524.756-0.004
5Y4.1015.757-1.656
10Y3.7506.338-2.588
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Coherus BioSciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Coherus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Coherus to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.11 means that Coherus assets are financed with 110.7% credit (debt) and the remaining percentage (100% - 110.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Coherus BioSciences Inc:

  • The MRQ is 1.107. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.254. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.107TTM1.254-0.147
TTM1.254YOY1.248+0.006
TTM1.2545Y0.979+0.274
5Y0.97910Y0.943+0.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1070.330+0.777
TTM1.2540.342+0.912
YOY1.2480.287+0.961
5Y0.9790.368+0.611
10Y0.9430.382+0.561
1.4.2. Debt to Equity Ratio

Measures if Coherus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Coherus to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Coherus BioSciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y4.070-4.070
5Y4.07010Y3.766+0.304
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.365-0.365
TTM-0.415-0.415
YOY-0.370-0.370
5Y4.0700.443+3.627
10Y3.7660.476+3.290
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Coherus BioSciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Coherus generates.

  • Above 15 is considered overpriced but always compare Coherus to the Biotechnology industry mean.
  • A PE ratio of 0.73 means the investor is paying $0.73 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Coherus BioSciences Inc:

  • The EOD is 0.424. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.729. Based on the earnings, the company is cheap. +2
  • The TTM is -1.508. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.424MRQ0.729-0.305
MRQ0.729TTM-1.508+2.237
TTM-1.508YOY-3.443+1.934
TTM-1.5085Y4.151-5.660
5Y4.15110Y-1.303+5.455
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.424-2.341+2.765
MRQ0.729-2.997+3.726
TTM-1.508-2.882+1.374
YOY-3.443-3.553+0.110
5Y4.151-6.262+10.413
10Y-1.303-6.288+4.985
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Coherus BioSciences Inc:

  • The EOD is -0.933. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.604. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.520. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.933MRQ-1.604+0.671
MRQ-1.604TTM-3.520+1.917
TTM-3.520YOY-4.135+0.614
TTM-3.5205Y-5.340+1.820
5Y-5.34010Y-3.917-1.423
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.933-2.932+1.999
MRQ-1.604-3.739+2.135
TTM-3.520-3.776+0.256
YOY-4.135-4.917+0.782
5Y-5.340-7.942+2.602
10Y-3.917-8.503+4.586
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Coherus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -3.67 means the investor is paying $-3.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Coherus BioSciences Inc:

  • The EOD is -2.132. Based on the equity, the company is expensive. -2
  • The MRQ is -3.666. Based on the equity, the company is expensive. -2
  • The TTM is -2.914. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.132MRQ-3.666+1.534
MRQ-3.666TTM-2.914-0.752
TTM-2.914YOY-14.665+11.752
TTM-2.9145Y-21.733+18.820
5Y-21.73310Y-14.003-7.731
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.1321.843-3.975
MRQ-3.6662.249-5.915
TTM-2.9142.301-5.215
YOY-14.6652.412-17.077
5Y-21.7333.782-25.515
10Y-14.0034.212-18.215
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Coherus BioSciences Inc.

3.1. Institutions holding Coherus BioSciences Inc

Institutions are holding 75.031% of the shares of Coherus BioSciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31BlackRock Inc9.7890.000611230522-844173-6.9913
2024-03-31Rubric Capital Management LP9.06510.734610400000100047932531.5323
2024-03-31Vanguard Group Inc8.78580.000510079554-277858-2.6827
2024-03-31Temasek Holdings Ltd.6.43370.0977738111600
2024-03-31Kohlberg Kravis Roberts & Co LP2.64640.1872303607600
2024-03-31Morgan Stanley - Brokerage Accounts2.32220.0005266416959431628.713
2024-03-31Bank of America Corp2.11570.0005242722530842114.5564
2024-03-31Geode Capital Management, LLC1.92080.000522036941220935.8653
2024-03-31Barclays PLC1.80030.00172065351-1419044-40.7257
2024-03-31State Street Corporation1.73960.00021995738-68588-3.3225
2024-03-31CAM Group Holding A/S1.68090.0525192846400
2024-03-31Goldman Sachs Group Inc1.49450.00071714574394242.3535
2024-03-31Two Sigma Investments LLC1.27440.00821462013116610.804
2024-03-31Millennium Management LLC1.0960.00131257363-1584956-55.7628
2024-03-31Disciplined Growth Investors Inc1.09470.05481255937892107.6462
2024-03-31Tejara Capital Ltd0.91990.9269105538610553860
2024-03-31Peregrine Capital Management,LLC0.8860.06961016455-73506-6.7439
2024-03-31AlphaCentric Advisors, LLC0.87161.4416100000000
2024-03-31CM Management, LLC0.87162.0074100000017600021.3592
2024-03-31Northern Trust Corp0.80330.0004921641-44377-4.5938
Total 57.61155.587466095278+8088802+12.2%

3.2. Funds holding Coherus BioSciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Vanguard Total Stock Mkt Idx Inv2.90230.0004332969800
2024-05-30iShares Russell 2000 ETF2.07690.00762382717181280.7666
2024-04-30C WorldWide Healthcare Select 1A1.68090.4913192846400
2024-03-31Vanguard Strategic Equity Inv1.48660.0484170551200
2024-03-31Vanguard Explorer Inv1.4760.0177169330300
2023-11-30MEDICAL BioHealth EUR Acc1.34730.5285154575500
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr1.20860.0028138656200
2024-03-31Fidelity Small Cap Index0.9060.00931039388185091.813
2024-03-31AlphaCentric LifeSci Healthcare I0.87162.3149100000000
2024-04-30BlackRock Advantage Small Cap Core Instl0.8240.05594529000
2023-10-13Pictet Biopharmaceutical Mother0.81540.237935500512567121.1934
2024-04-30Delaware Healthcare I0.78450.233690000000
2024-05-30iShares Biotechnology ETF0.65150.0199747453-2824-0.3764
2024-05-30iShares Russell 2000 Growth ETF0.64840.012874386900
2024-05-31State St Russell Sm/Mid Cp® Indx NL Cl C0.55810.002864031200
2024-04-30Fidelity Extended Market Index0.47140.0029540793-4901-0.8981
2023-12-31Disciplined Growth - Small Cap Growth0.4030.48344622914622910
2024-05-31Schwab US Small-Cap ETF™0.40210.005246125700
2024-04-30Vanguard Russell 2000 ETF0.34170.008139206213440.344
2024-05-31State St Russell Sm Cap® Indx SL Cl I0.33160.007438038800
Total 20.18794.48923160614+1005114+4.3%

3.3. Insider Transactions

Insiders are holding 1.392% of the shares of Coherus BioSciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-22Dennis M LanfearSELL2231002.02
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Coherus BioSciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0340.265+290%-0.456+144%-0.016+102%-0.007+101%
Book Value Per Share---0.652-1.256+93%-0.989+52%0.244-367%0.202-423%
Current Ratio--1.1661.682-31%4.905-76%4.179-72%3.802-69%
Debt To Asset Ratio--1.1071.254-12%1.248-11%0.979+13%0.943+17%
Debt To Equity Ratio----0%-0%4.070-100%3.766-100%
Dividend Per Share----0%0.108-100%0.022-100%0.011-100%
Eps--0.820-0.148+118%-0.591+172%-0.209+126%-0.392+148%
Free Cash Flow Per Share---0.373-0.325-13%-0.561+51%-0.122-67%-0.243-35%
Free Cash Flow To Equity Per Share---0.365-0.180-51%-0.430+18%0.056-753%0.037-1086%
Gross Profit Margin--1.0001.0000%1.040-4%1.008-1%1.0040%
Intrinsic Value_10Y_max---16.794--------
Intrinsic Value_10Y_min---28.798--------
Intrinsic Value_1Y_max---1.078--------
Intrinsic Value_1Y_min---1.710--------
Intrinsic Value_3Y_max---3.699--------
Intrinsic Value_3Y_min---6.186--------
Intrinsic Value_5Y_max---6.877--------
Intrinsic Value_5Y_min---11.777--------
Market Cap159469140.000-88%300016630.690400252367.673-25%906622215.000-67%1428970100.035-79%1671701431.017-82%
Net Profit Margin--1.335-0.199+115%-1.687+226%-0.541+140%-18.242+1466%
Operating Margin---0.464-0.553+19%-1.432+209%-0.505+9%-17.701+3718%
Operating Ratio--1.4641.557-6%2.432-40%1.505-3%35.914-96%
Pb Ratio-2.132+42%-3.666-2.914-21%-14.665+300%-21.733+493%-14.003+282%
Pe Ratio0.424-72%0.729-1.508+307%-3.443+572%4.151-82%-1.303+279%
Price Per Share1.390-72%2.3903.433-30%7.903-70%12.444-81%14.566-84%
Price To Free Cash Flow Ratio-0.933+42%-1.604-3.520+120%-4.135+158%-5.340+233%-3.917+144%
Price To Total Gains Ratio1.344-72%2.3117.220-68%-25.790+1216%9.011-74%545.319-100%
Quick Ratio--1.0101.492-32%4.752-79%4.101-75%3.750-73%
Return On Assets--0.135-0.038+128%-0.149+210%-0.040+130%-0.147+209%
Return On Equity----0%-0%-0.4650%-0.6970%
Total Gains Per Share--1.0340.265+290%-0.348+134%0.006+18031%0.004+27891%
Usd Book Value---81844000.000-145908000.000+78%-113421750.000+39%27611500.000-396%22993725.000-456%
Usd Book Value Change Per Share--1.0340.265+290%-0.456+144%-0.016+102%-0.007+101%
Usd Book Value Per Share---0.652-1.256+93%-0.989+52%0.244-367%0.202-423%
Usd Dividend Per Share----0%0.108-100%0.022-100%0.011-100%
Usd Eps--0.820-0.148+118%-0.591+172%-0.209+126%-0.392+148%
Usd Free Cash Flow---46766000.000-38263000.000-18%-64346750.000+38%-14206100.000-70%-28020725.000-40%
Usd Free Cash Flow Per Share---0.373-0.325-13%-0.561+51%-0.122-67%-0.243-35%
Usd Free Cash Flow To Equity Per Share---0.365-0.180-51%-0.430+18%0.056-753%0.037-1086%
Usd Market Cap159469140.000-88%300016630.690400252367.673-25%906622215.000-67%1428970100.035-79%1671701431.017-82%
Usd Price Per Share1.390-72%2.3903.433-30%7.903-70%12.444-81%14.566-84%
Usd Profit--102875000.000-14822000.000+114%-72541250.000+171%-25285750.000+125%-34644700.000+134%
Usd Revenue--77063000.00075467750.000+2%45840750.000+68%83334850.000-8%48898975.000+58%
Usd Total Gains Per Share--1.0340.265+290%-0.348+134%0.006+18031%0.004+27891%
 EOD+2 -6MRQTTM+18 -13YOY+23 -115Y+14 -2110Y+14 -21

4.2. Fundamental Score

Let's check the fundamental score of Coherus BioSciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.424
Price to Book Ratio (EOD)Between0-1-2.132
Net Profit Margin (MRQ)Greater than01.335
Operating Margin (MRQ)Greater than0-0.464
Quick Ratio (MRQ)Greater than11.010
Current Ratio (MRQ)Greater than11.166
Debt to Asset Ratio (MRQ)Less than11.107
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.050.135
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Coherus BioSciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.963
Ma 20Greater thanMa 501.662
Ma 50Greater thanMa 1001.889
Ma 100Greater thanMa 2002.136
OpenGreater thanClose1.410
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Income before Tax  -75,72932,860-42,8692,848-40,021-39,632-79,653182,528102,875
Net Income  -74,78031,911-42,8693,228-39,641-40,012-79,653182,528102,875
Net Income from Continuing Operations  -75,72932,860-42,8693,228-39,641-40,012-79,653182,528102,875



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets763,545
Total Liabilities845,389
Total Stockholder Equity-81,844
 As reported
Total Liabilities 845,389
Total Stockholder Equity+ -81,844
Total Assets = 763,545

Assets

Total Assets763,545
Total Current Assets627,477
Long-term Assets136,068
Total Current Assets
Cash And Cash Equivalents 259,775
Net Receivables 284,145
Inventory 61,978
Other Current Assets 21,579
Total Current Assets  (as reported)627,477
Total Current Assets  (calculated)627,477
+/- 0
Long-term Assets
Property Plant Equipment 4,188
Intangible Assets 57,104
Long-term Assets Other 74,324
Long-term Assets  (as reported)136,068
Long-term Assets  (calculated)135,616
+/- 452

Liabilities & Shareholders' Equity

Total Current Liabilities538,303
Long-term Liabilities307,086
Total Stockholder Equity-81,844
Total Current Liabilities
Short-term Debt 176,811
Short Long Term Debt 175,000
Accounts payable 38,289
Other Current Liabilities 186,545
Total Current Liabilities  (as reported)538,303
Total Current Liabilities  (calculated)576,645
+/- 38,342
Long-term Liabilities
Long term Debt 299,672
Capital Lease Obligations 6,491
Long-term Liabilities Other 1,632
Long-term Liabilities  (as reported)307,086
Long-term Liabilities  (calculated)307,795
+/- 709
Total Stockholder Equity
Common Stock11
Retained Earnings -1,476,625
Accumulated Other Comprehensive Income -272
Other Stockholders Equity 1,395,042
Total Stockholder Equity (as reported)-81,844
Total Stockholder Equity (calculated)-81,844
+/-0
Other
Capital Stock11
Cash and Short Term Investments 259,775
Common Stock Shares Outstanding 125,530
Current Deferred Revenue136,658
Liabilities and Stockholders Equity 763,545
Net Debt 221,388
Net Invested Capital 392,828
Net Working Capital 89,174
Property Plant and Equipment Gross 24,786
Short Long Term Debt Total 481,163



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302012-12-31
> Total Assets 
26,533
0
47,447
0
122,183
129,182
187,221
153,153
249,546
202,312
212,384
226,236
251,101
192,357
178,485
227,495
172,251
189,758
162,611
128,462
188,313
141,462
99,467
186,115
240,456
327,383
408,927
466,539
756,611
803,733
841,649
693,303
739,542
741,726
679,334
593,387
546,003
550,907
480,847
402,426
469,591
583,783
629,604
763,545
763,545629,604583,783469,591402,426480,847550,907546,003593,387679,334741,726739,542693,303841,649803,733756,611466,539408,927327,383240,456186,11599,467141,462188,313128,462162,611189,758172,251227,495178,485192,357251,101226,236212,384202,312249,546153,153187,221129,182122,183047,447026,533
   > Total Current Assets 
0
0
45,677
0
114,708
118,875
150,392
143,897
206,088
153,691
158,226
211,583
236,834
177,319
124,947
208,260
153,342
171,605
126,911
112,241
172,781
130,314
72,356
159,158
212,101
297,748
374,731
395,183
709,969
726,920
790,393
617,261
660,013
673,039
633,469
512,443
446,784
448,275
416,696
344,034
385,484
444,365
475,631
627,477
627,477475,631444,365385,484344,034416,696448,275446,784512,443633,469673,039660,013617,261790,393726,920709,969395,183374,731297,748212,101159,15872,356130,314172,781112,241126,911171,605153,342208,260124,947177,319236,834211,583158,226153,691206,088143,897150,392118,875114,708045,67700
       Cash And Cash Equivalents 
14,548
0
39,554
0
108,869
100,875
150,392
115,136
206,088
153,691
158,226
179,558
220,916
159,677
124,947
124,924
73,352
135,557
126,911
82,021
130,005
101,202
72,356
81,515
105,927
165,116
177,668
193,252
224,617
292,465
541,158
259,489
329,738
360,540
417,195
325,680
275,484
286,805
63,547
16,145
72,920
80,259
102,891
259,775
259,775102,89180,25972,92016,14563,547286,805275,484325,680417,195360,540329,738259,489541,158292,465224,617193,252177,668165,116105,92781,51572,356101,202130,00582,021126,911135,55773,352124,924124,947159,677220,916179,558158,226153,691206,088115,136150,392100,875108,869039,554014,548
       Short-term Investments 
50
0
50
0
50
50
60
60
60
60
60
60
60
60
60
49,900
44,980
14,493
60
13,143
29,813
15,968
0
14,918
5,991
5,377
0
0
231,882
210,966
0
140,014
124,683
108,167
0
0
0
0
128,134
111,944
71,792
50,818
14,857
0
014,85750,81871,792111,944128,1340000108,167124,683140,0140210,966231,882005,3775,99114,918015,96829,81313,1436014,49344,98049,9006060606060606060605050050050
       Net Receivables 
0
0
385
0
0
0
4,232
3,852
1,454
540
1,560
1,195
419
419
1,859
26
0
0
0
0
0
0
-1,742
46,476
77,385
89,646
141,992
167,450
172,486
160,707
157,046
140,410
141,825
136,346
123,022
117,039
115,711
91,186
109,964
101,458
141,308
216,511
260,522
284,145
284,145260,522216,511141,308101,458109,96491,186115,711117,039123,022136,346141,825140,410157,046160,707172,486167,450141,99289,64677,38546,476-1,742000000261,8594194191,1951,5605401,4543,8524,23200038500
       Inventory 
0
0
0
0
0
0
-8,199
20,174
-6,489
-3,873
-4,357
26,045
15,068
16,705
-4,845
30,544
0
0
0
0
0
0
1,659
2,312
22,798
37,609
55,071
16,436
80,984
35,247
92,189
51,613
39,668
37,583
93,252
36,945
31,744
27,719
115,051
114,487
63,989
66,783
62,605
61,978
61,97862,60566,78363,989114,487115,05127,71931,74436,94593,25237,58339,66851,61392,18935,24780,98416,43655,07137,60922,7982,3121,65900000030,544-4,84516,70515,06826,045-4,357-3,873-6,48920,174-8,199000000
   > Long-term Assets 
0
0
1,770
0
7,475
10,307
36,829
9,256
43,458
48,621
54,158
14,653
14,267
15,038
53,538
19,235
18,909
18,153
35,700
16,221
15,532
11,148
27,111
26,957
28,355
29,635
34,196
71,356
46,642
76,813
51,256
76,042
79,529
68,687
45,865
80,944
99,219
102,632
64,151
58,392
84,107
139,418
153,973
136,068
136,068153,973139,41884,10758,39264,151102,63299,21980,94445,86568,68779,52976,04251,25676,81346,64271,35634,19629,63528,35526,95727,11111,14815,53216,22135,70018,15318,90919,23553,53815,03814,26714,65354,15848,62143,4589,25636,82910,3077,47501,77000
       Property Plant Equipment 
1,605
0
1,743
0
3,037
3,680
4,472
5,104
6,341
8,652
10,504
10,296
9,904
10,675
10,772
14,873
14,547
13,791
12,773
11,859
11,170
6,786
6,660
12,895
11,999
16,990
16,489
18,359
21,319
21,117
20,064
9,670
9,130
8,505
7,813
7,998
9,553
9,571
8,754
7,724
6,929
6,069
11,031
4,188
4,18811,0316,0696,9297,7248,7549,5719,5537,9987,8138,5059,1309,67020,06421,11721,31918,35916,48916,99011,99912,8956,6606,78611,17011,85912,77313,79114,54714,87310,77210,6759,90410,29610,5048,6526,3415,1044,4723,6803,03701,74301,605
       Goodwill 
0
0
0
0
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
943
0
0
0
900
0
0
943
943
0
0943943009000009439439439439439439439439439439439439439439439439439439439439439439439439439439439439439439430000
       Intangible Assets 
0
0
0
0
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
2,620
3,563
3,563
5,996
5,031
5,870
5,809
45,581
70,730
57,104
57,10470,73045,5815,8095,8705,0315,9963,5633,5632,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6202,6200000
       Long-term Assets Other 
0
0
27
0
875
3,064
28,794
589
33,554
36,406
40,091
794
800
800
39,203
799
799
799
19,364
799
799
799
16,888
10,499
12,793
9,082
14,144
49,434
21,760
52,133
27,629
62,809
66,836
56,619
34,489
69,383
86,103
87,065
49,466
44,798
71,369
86,825
87
74,324
74,3248786,82571,36944,79849,46687,06586,10369,38334,48956,61966,83662,80927,62952,13321,76049,43414,1449,08212,79310,49916,88879979979919,36479979979939,20380080079440,09136,40633,55458928,7943,06487502700
> Total Liabilities 
17,341
0
89,829
0
107,607
120,003
120,464
115,160
153,182
162,272
219,313
293,114
313,049
160,635
159,131
150,536
141,394
134,851
132,076
131,550
126,482
129,068
138,058
224,630
244,441
271,360
303,713
309,264
543,234
548,002
560,675
565,632
583,322
610,966
581,608
580,824
568,632
648,040
618,265
598,933
644,355
717,382
823,029
845,389
845,389823,029717,382644,355598,933618,265648,040568,632580,824581,608610,966583,322565,632560,675548,002543,234309,264303,713271,360244,441224,630138,058129,068126,482131,550132,076134,851141,394150,536159,131160,635313,049293,114219,313162,272153,182115,160120,464120,003107,607089,829017,341
   > Total Current Liabilities 
11,253
0
53,701
0
44,563
48,077
51,783
51,913
69,947
82,519
106,018
92,920
108,284
58,386
56,376
47,296
35,947
31,430
28,395
27,624
22,198
24,537
33,261
41,407
61,226
93,587
114,969
119,011
66,229
133,432
81,529
257,601
287,052
320,348
79,027
153,748
140,754
171,319
54,461
55,697
169,440
239,659
331,771
538,303
538,303331,771239,659169,44055,69754,461171,319140,754153,74879,027320,348287,052257,60181,529133,43266,229119,011114,96993,58761,22641,40733,26124,53722,19827,62428,39531,43035,94747,29656,37658,386108,28492,920106,01882,51969,94751,91351,78348,07744,563053,701011,253
       Short-term Debt 
0
0
4,203
0
1,589
2,296
11,231
13,271
19,280
25,170
24,133
3,494
2,430
2,860
877
2,109
18,429
101,258
233
233
102,333
0
0
2,140
0
0
0
0
0
10,729
233
110,275
122,423
128,902
3,492
3,370
3,988
4,097
4,318
4,436
4,446
4,469
2,145
176,811
176,8112,1454,4694,4464,4364,3184,0973,9883,3703,492128,902122,423110,27523310,729000002,14000102,333233233101,25818,4292,1098772,8602,4303,49424,13325,17019,28013,27111,2312,2961,58904,20300
       Short Long Term Debt 
0
0
0
0
0
0
1,192
0
0
0
1,330
0
1,200
1,150
100,256
1,070
100,916
101,258
101,608
101,966
102,333
0
0
2,140
0
0
0
0
0
0
0
106,987
119,011
125,278
0
0
0
0
0
0
0
0
0
175,000
175,000000000000125,278119,011106,98700000002,14000102,333101,966101,608101,258100,9161,070100,2561,1501,20001,3300001,192000000
       Accounts payable 
3,902
0
3,685
0
8,415
9,374
10,798
14,594
19,600
28,278
29,496
21,398
19,863
25,743
20,583
14,669
16,140
10,144
15,714
14,365
13,303
7,637
15,294
11,173
19,273
13,709
25,985
20,485
21,179
11,990
15,201
15,482
14,568
45,707
16,159
21,092
17,486
9,917
11,526
23,231
29,278
37,092
35,219
38,289
38,28935,21937,09229,27823,23111,5269,91717,48621,09216,15945,70714,56815,48215,20111,99021,17920,48525,98513,70919,27311,17315,2947,63713,30314,36515,71410,14416,14014,66920,58325,74319,86321,39829,49628,27819,60014,59410,7989,3748,41503,68503,902
       Other Current Liabilities 
7,351
0
31,530
0
9,427
11,231
5,762
56
62
223
1,438
17,425
23,533
27,256
32,954
28,779
308
21,286
3,631
13,259
8,895
16,900
17,967
30,234
41,953
79,878
88,984
98,526
45,050
121,442
66,328
131,844
150,061
145,739
145,676
129,286
119,280
157,305
38,617
28,030
140,162
202,567
294,407
186,545
186,545294,407202,567140,16228,03038,617157,305119,280129,286145,676145,739150,061131,84466,328121,44245,05098,52688,98479,87841,95330,23417,96716,9008,89513,2593,63121,28630828,77932,95427,25623,53317,4251,43822362565,76211,2319,427031,53007,351
   > Long-term Liabilities 
0
0
36,128
0
63,044
71,926
120,464
63,247
153,182
162,272
219,313
200,194
204,765
102,249
159,131
103,240
105,447
103,421
132,076
103,926
104,284
104,531
138,058
183,223
244,441
271,360
303,713
190,253
477,005
414,570
479,146
308,031
296,270
290,618
502,581
427,076
427,878
476,721
563,804
543,236
474,915
477,723
491,258
307,086
307,086491,258477,723474,915543,236563,804476,721427,878427,076502,581290,618296,270308,031479,146414,570477,005190,253303,713271,360244,441183,223138,058104,531104,284103,926132,076103,421105,447103,240159,131102,249204,765200,194219,313162,272153,18263,247120,46471,92663,044036,12800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
74,492
74,720
74,953
75,192
75,437
75,687
75,944
76,206
76,474
76,750
77,031
77,319
176,610
177,174
177,773
178,386
179,187
375,666
376,522
377,395
298,037
287,075
281,895
381,160
224,607
224,928
225,250
225,575
225,900
226,228
0
0
0
000226,228225,900225,575225,250224,928224,607381,160281,895287,075298,037377,395376,522375,666179,187178,386177,773177,174176,61077,31977,03176,75076,47476,20675,94475,68775,43775,19274,95374,72074,49200000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-4,203
0
-1,589
-2,296
-11,231
-13,271
-19,280
-25,170
-24,133
-3,494
-2,430
-2,860
-877
-2,109
-18,429
-101,258
-233
-233
-102,333
0
0
4,409
5,977
10,827
10,256
11,138
11,304
0
9,715
-97,743
-110,567
-117,305
7,251
6,518
6,811
6,123
5,046
3,806
2,622
1,436
5,328
-170,320
-170,3205,3281,4362,6223,8065,0466,1236,8116,5187,251-117,305-110,567-97,7439,715011,30411,13810,25610,8275,9774,40900-102,333-233-233-101,258-18,429-2,109-877-2,860-2,430-3,494-24,133-25,170-19,280-13,271-11,231-2,296-1,5890-4,20300
       Warrants
0
0
0
0
0
322,328
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000322,32800000
       Long-term Liabilities Other 
0
0
0
0
0
28,400
28,782
28,844
44,744
46,306
67,957
92,729
103,253
26,701
26,894
27,078
29,760
27,477
27,475
27,452
27,534
27,500
27,478
64
64
59
102
102
102
38,048
37,627
9,994
751
8,723
94,301
202,469
202,950
251,471
253,996
249,626
248,687
3,513
11,459
1,632
1,63211,4593,513248,687249,626253,996251,471202,950202,46994,3018,7237519,99437,62738,04810210210259646427,47827,50027,53427,45227,47527,47729,76027,07826,89426,701103,25392,72967,95746,30644,74428,84428,78228,40000000
       Deferred Long Term Liability 
0
0
0
0
0
43,526
39,899
34,403
38,491
33,447
45,338
32,973
26,792
595
669
725
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000072566959526,79232,97345,33833,44738,49134,40339,89943,52600000
> Total Stockholder Equity
9,192
0
-42,382
0
14,689
9,334
66,757
38,151
96,364
40,040
-6,929
-66,006
-60,893
32,872
19,354
78,176
32,140
56,195
30,535
-1,794
63,172
12,394
-38,591
-38,515
-3,985
56,023
105,214
157,275
213,377
255,731
280,974
127,671
156,220
130,760
97,726
12,563
-22,629
-97,133
-137,418
-196,507
-174,764
-133,599
-193,425
-81,844
-81,844-193,425-133,599-174,764-196,507-137,418-97,133-22,62912,56397,726130,760156,220127,671280,974255,731213,377157,275105,21456,023-3,985-38,515-38,59112,39463,172-1,79430,53556,19532,14078,17619,35432,872-60,893-66,006-6,92940,04096,36438,15166,7579,33414,6890-42,38209,192
   Common Stock
1
0
1
0
1
1
3
3
4
4
4
4
4
4
5
5
5
6
6
6
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
8
8
9
11
11
11
11111198877777777777777777766655544444433110101
   Retained Earnings Total Equity000-1,460,206-1,417,337-1,341,608-1,282,738-1,196,088-1,145,938-1,049,854-1,004,129-965,601-935,701-762,754-772,462-800,395-859,426-894,998-934,225-981,268-1,004,835-984,831-922,235-863,427-819,789-775,492-726,425-667,436-612,100-537,322-461,401-545,340-475,373-409,985-357,594-286,260-227,450-186,725-157,59100000
   Accumulated Other Comprehensive Income 
0
0
-625
0
32
-128
-525
-648
-520
-473
-401
-449
-524
-562
-630
-807
-673
-745
-750
-764
-537
-420
-282
-418
-511
-452
-558
50
-257
-255
-270
-307
-267
-273
-270
-272
-270
-270
-249
-278
-297
-265
-248
-272
-272-248-265-297-278-249-270-270-272-270-273-267-307-270-255-25750-558-452-511-418-282-420-537-764-750-745-673-807-630-562-524-449-401-473-520-648-525-128320-62500
   Capital Surplus 
0
0
0
0
0
5,888
254,048
266,246
383,522
398,636
404,175
409,812
484,967
494,831
558,474
691,078
700,244
783,359
808,060
818,753
927,129
935,042
946,515
966,731
977,787
990,693
1,000,763
1,016,644
1,014,022
1,028,441
1,043,991
1,063,672
1,122,081
1,135,155
1,147,843
1,158,766
1,173,722
1,185,868
1,204,431
1,221,100
1,285,730
0
0
0
0001,285,7301,221,1001,204,4311,185,8681,173,7221,158,7661,147,8431,135,1551,122,0811,063,6721,043,9911,028,4411,014,0221,016,6441,000,763990,693977,787966,731946,515935,042927,129818,753808,060783,359700,244691,078558,474494,831484,967409,812404,175398,636383,522266,246254,0485,88800000
   Treasury Stock00000000000000000000000000000000-66,878-6,929-40,040-96,364-37,993-66,757-151,98500000
   Other Stockholders Equity 
0
0
3,139
0
3,151
5,888
254,048
266,246
383,522
398,636
404,175
409,812
484,967
494,831
558,474
691,078
700,244
783,359
808,060
818,753
927,129
935,042
946,515
966,731
977,787
990,693
1,000,763
1,016,644
1,014,022
1,028,441
1,043,991
1,063,672
1,122,081
1,135,155
1,147,843
1,158,766
1,173,722
1,185,868
1,204,431
1,221,100
1,285,730
1,366,502
1,386,312
1,395,042
1,395,0421,386,3121,366,5021,285,7301,221,1001,204,4311,185,8681,173,7221,158,7661,147,8431,135,1551,122,0811,063,6721,043,9911,028,4411,014,0221,016,6441,000,763990,693977,787966,731946,515935,042927,129818,753808,060783,359700,244691,078558,474494,831484,967409,812404,175398,636383,522266,246254,0485,8883,15103,13900



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue257,244
Cost of Revenue-162,783
Gross Profit94,46194,461
 
Operating Income (+$)
Gross Profit94,461
Operating Expense-287,660
Operating Income-193,199-193,199
 
Operating Expense (+$)
Research Development102,045
Selling General Administrative192,015
Selling And Marketing Expenses0
Operating Expense287,660294,060
 
Net Interest Income (+$)
Interest Income0
Interest Expense-40,542
Other Finance Cost-0
Net Interest Income-40,542
 
Pretax Income (+$)
Operating Income-193,199
Net Interest Income-40,542
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-238,272-148,126
EBIT - interestExpense = -233,741
-238,272
-197,350
Interest Expense40,542
Earnings Before Interest and Taxes (EBIT)-193,199-197,730
Earnings Before Interest and Taxes (EBITDA)-189,408
 
After tax Income (+$)
Income Before Tax-238,272
Tax Provision--380
Net Income From Continuing Ops-237,892-237,892
Net Income-237,892
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses450,443
Total Other Income/Expenses Net-45,07340,542
 

Technical Analysis of Coherus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Coherus. The general trend of Coherus is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Coherus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Coherus BioSciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.4301 < 1.81 < 1.84.

The bearish price targets are: .

Tweet this
Coherus BioSciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Coherus BioSciences Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Coherus BioSciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Coherus BioSciences Inc. The current macd is -0.11085391.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Coherus price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Coherus. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Coherus price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Coherus BioSciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartCoherus BioSciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Coherus BioSciences Inc. The current adx is 33.23.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Coherus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Coherus BioSciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Coherus BioSciences Inc. The current sar is 1.781618.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Coherus BioSciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Coherus BioSciences Inc. The current rsi is 29.96. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Coherus BioSciences Inc Daily Relative Strength Index (RSI) ChartCoherus BioSciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Coherus BioSciences Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Coherus price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Coherus BioSciences Inc Daily Stochastic Oscillator ChartCoherus BioSciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Coherus BioSciences Inc. The current cci is -242.03110956.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Coherus BioSciences Inc Daily Commodity Channel Index (CCI) ChartCoherus BioSciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Coherus BioSciences Inc. The current cmo is -47.82502036.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Coherus BioSciences Inc Daily Chande Momentum Oscillator (CMO) ChartCoherus BioSciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Coherus BioSciences Inc. The current willr is -89.79591837.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Coherus BioSciences Inc Daily Williams %R ChartCoherus BioSciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Coherus BioSciences Inc.

Coherus BioSciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Coherus BioSciences Inc. The current atr is 0.12222257.

Coherus BioSciences Inc Daily Average True Range (ATR) ChartCoherus BioSciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Coherus BioSciences Inc. The current obv is -12,750,283.

Coherus BioSciences Inc Daily On-Balance Volume (OBV) ChartCoherus BioSciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Coherus BioSciences Inc. The current mfi is 37.71.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Coherus BioSciences Inc Daily Money Flow Index (MFI) ChartCoherus BioSciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Coherus BioSciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-06-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Coherus BioSciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Coherus BioSciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.963
Ma 20Greater thanMa 501.662
Ma 50Greater thanMa 1001.889
Ma 100Greater thanMa 2002.136
OpenGreater thanClose1.410
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Coherus with someone you think should read this too:
  • Are you bullish or bearish on Coherus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Coherus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Coherus BioSciences Inc

I send you an email if I find something interesting about Coherus BioSciences Inc.


Stay informed about Coherus BioSciences Inc.

Receive notifications about Coherus BioSciences Inc in your mailbox!